Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy of both treatments has not been directly compared...

Descripción completa

Detalles Bibliográficos
Autores: Alonso-García, Miriam, Sánchez-Gastaldo, Amparo, Muñoz-Fuentes, Miguel A., Molina Pinelo, Sonia, Boyero, Laura, Benedetti, Johana Cristina, Bernabé-Caro, Reyes
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/139816
Acceso en línea:https://hdl.handle.net/11441/139816
https://doi.org/10.3390/ph15050533
Access Level:acceso abierto
Palabra clave:Atezolizumab
Immune checkpoint inhibitors (ICIs)
Immunotherapy
Nivolumab
Non small cell lung cancer (NSCLC)
Real-world data
id ES_1adee49dfe75ebf606b8d5cf3e2ffb47
oai_identifier_str oai:idus.us.es:11441/139816
network_acronym_str ES
network_name_str España
repository_id_str
spelling Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung CancerAlonso-García, MiriamSánchez-Gastaldo, AmparoMuñoz-Fuentes, Miguel A.Molina Pinelo, SoniaBoyero, LauraBenedetti, Johana CristinaBernabé-Caro, ReyesAtezolizumabImmune checkpoint inhibitors (ICIs)ImmunotherapyNivolumabNon small cell lung cancer (NSCLC)Real-world dataNivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy of both treatments has not been directly compared in clinical trials. This retrospective, single-centre study was performed from June 2015 to December 2020 and included a cohort of 158 previously treated patients with stage IV or recurrent NSCLC who received PD-1 (nivolumab) (n = 89) or PD-L1 (atezolizumab) (n = 69) inhibitors at the Virgen del Rocío Hospital in Seville. The objective response rate (ORR) was 22.5% in the nivolumab group and 14.5% in the atezolizumab group (p = 0.140). Multivariate analysis did not show significant differences between the two groups for PFS and OS (PFS hazard ratio (HR): 0.80, 95% confidence interval (CI): 0.55–1.17, p = 0.260; OS HR: 0.79, 95% CI: 0.52–1.21, p = 0.281). Adverse events of all grades occurred in 68 patients in the nivolumab group (76.4%) and in 34 patients in the atezolizumab group (49.3%) (p < 0.001). Atezolizumab and nivolumab did not show statistically significant differences in survival outcomes in patients with NSCLC, even when stratified by histological subtype (squamous versus nonsquamous). However, the safety analysis suggested a more favourable toxicity profile for atezolizumab.MDPIMedicinaCTS629: Oncología molecular y nuevas terapiasConsejería de Sanidad y Bienestar Social, Junta de AndalucíaPlan Andaluz de Investigación, Desarrollo e Innovación, Junta de AndalucíaInstituto de Salud Carlos III2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/139816https://doi.org/10.3390/ph15050533reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésPharmaceuticals, 15 (5), 533.PI-0046-2012PY20_00992PI17/00033PI20/01109https://www.mdpi.com/1424-8247/15/5/533info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1398162026-06-17T12:51:07Z
dc.title.none.fl_str_mv Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
title Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
spellingShingle Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Alonso-García, Miriam
Atezolizumab
Immune checkpoint inhibitors (ICIs)
Immunotherapy
Nivolumab
Non small cell lung cancer (NSCLC)
Real-world data
title_short Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
title_full Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
title_fullStr Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
title_full_unstemmed Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
title_sort Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
dc.creator.none.fl_str_mv Alonso-García, Miriam
Sánchez-Gastaldo, Amparo
Muñoz-Fuentes, Miguel A.
Molina Pinelo, Sonia
Boyero, Laura
Benedetti, Johana Cristina
Bernabé-Caro, Reyes
author Alonso-García, Miriam
author_facet Alonso-García, Miriam
Sánchez-Gastaldo, Amparo
Muñoz-Fuentes, Miguel A.
Molina Pinelo, Sonia
Boyero, Laura
Benedetti, Johana Cristina
Bernabé-Caro, Reyes
author_role author
author2 Sánchez-Gastaldo, Amparo
Muñoz-Fuentes, Miguel A.
Molina Pinelo, Sonia
Boyero, Laura
Benedetti, Johana Cristina
Bernabé-Caro, Reyes
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Medicina
CTS629: Oncología molecular y nuevas terapias
Consejería de Sanidad y Bienestar Social, Junta de Andalucía
Plan Andaluz de Investigación, Desarrollo e Innovación, Junta de Andalucía
Instituto de Salud Carlos III
dc.subject.none.fl_str_mv Atezolizumab
Immune checkpoint inhibitors (ICIs)
Immunotherapy
Nivolumab
Non small cell lung cancer (NSCLC)
Real-world data
topic Atezolizumab
Immune checkpoint inhibitors (ICIs)
Immunotherapy
Nivolumab
Non small cell lung cancer (NSCLC)
Real-world data
description Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy of both treatments has not been directly compared in clinical trials. This retrospective, single-centre study was performed from June 2015 to December 2020 and included a cohort of 158 previously treated patients with stage IV or recurrent NSCLC who received PD-1 (nivolumab) (n = 89) or PD-L1 (atezolizumab) (n = 69) inhibitors at the Virgen del Rocío Hospital in Seville. The objective response rate (ORR) was 22.5% in the nivolumab group and 14.5% in the atezolizumab group (p = 0.140). Multivariate analysis did not show significant differences between the two groups for PFS and OS (PFS hazard ratio (HR): 0.80, 95% confidence interval (CI): 0.55–1.17, p = 0.260; OS HR: 0.79, 95% CI: 0.52–1.21, p = 0.281). Adverse events of all grades occurred in 68 patients in the nivolumab group (76.4%) and in 34 patients in the atezolizumab group (49.3%) (p < 0.001). Atezolizumab and nivolumab did not show statistically significant differences in survival outcomes in patients with NSCLC, even when stratified by histological subtype (squamous versus nonsquamous). However, the safety analysis suggested a more favourable toxicity profile for atezolizumab.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/139816
https://doi.org/10.3390/ph15050533
url https://hdl.handle.net/11441/139816
https://doi.org/10.3390/ph15050533
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Pharmaceuticals, 15 (5), 533.
PI-0046-2012
PY20_00992
PI17/00033
PI20/01109
https://www.mdpi.com/1424-8247/15/5/533
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404132379459584
score 15,301603

Similares en LA Referencia